Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aspirin Augmentation in Depression
NCT03152409Phase 2Terminated
- Start
- Nov 2018
- Primary completion
- Feb 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD) comparing Aspirin Augmentation with Placebo Augmentation (2 arms). Primary endpoint: Change in Hamilton Depression Scale Score at 8 weeks. Started Nov 2018; status: terminated.
02
Drugs
aspirin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03152409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03152409.